NASDAQ:ARGX - argenx Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $332.15
  • Forecasted Upside: 6.41 %
  • Number of Analysts: 17
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
▼ -3.66 (-1.16%)

This chart shows the closing price for ARGX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New argenx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARGX

Analyst Price Target is $332.15
▲ +6.41% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for argenx in the last 3 months. The average price target is $332.15, with a high forecast of $430.00 and a low forecast of $250.00. The average price target represents a 6.41% upside from the last price of $312.15.

This chart shows the closing price for ARGX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 17 polled investment analysts is to buy stock in argenx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 15 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 14 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/18/2021UBS GroupInitiated CoverageBuy$390.00Medium
6/8/2021WedbushLower Price TargetPositive ➝ Outperform$356.00 ➝ $344.00Low
6/7/2021Piper SandlerLower Price TargetNeutral$309.00 ➝ $250.00High
5/18/2021Morgan StanleyBoost Price TargetOverweight$321.00 ➝ $324.00Medium
5/16/2021Kepler Capital MarketsDowngradeHoldHigh
5/10/2021HC WainwrightUpgradeNeutral ➝ Buy$320.00 ➝ $400.00Medium
4/23/2021Redburn PartnersInitiated CoverageNeutralLow
4/19/2021Morgan StanleyLower Price TargetOverweight$326.00 ➝ $321.00Low
3/8/2021Morgan StanleyBoost Price TargetOverweight$311.00 ➝ $326.00Low
3/5/2021Kepler Capital MarketsReiterated RatingHoldMedium
3/5/2021HC WainwrightBoost Price TargetNeutral$265.00 ➝ $320.00Medium
2/18/2021CowenBoost Price TargetOutperform$317.00 ➝ $430.00Low
2/10/2021BarclaysReiterated RatingEqual WeightLow
2/4/2021Piper SandlerBoost Price Target$303.00 ➝ $309.00Low
2/2/2021Wells Fargo & CompanyBoost Price TargetEqual Weight$272.00 ➝ $326.00Low
2/1/2021Piper SandlerDowngradeOverweight ➝ Neutral$300.00 ➝ $303.00Low
2/1/2021JMP SecuritiesReiterated RatingPositive ➝ Outperform$307.00 ➝ $421.00Low
1/7/2021Wells Fargo & CompanyBoost Price TargetEqual Weight$249.00 ➝ $272.00N/A
1/7/2021JMP SecuritiesBoost Price TargetOutperform$271.00 ➝ $307.00N/A
1/4/2021GuggenheimDowngradeBuy ➝ NeutralN/A
12/16/2020Morgan StanleyBoost Price TargetOverweight$295.00 ➝ $311.00Medium
12/15/2020Truist FinancialBoost Price Target$275.00 ➝ $350.00Low
11/11/2020Morgan StanleyBoost Price TargetOverweight$281.00 ➝ $295.00Low
10/29/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
10/23/2020BarclaysReiterated RatingEqual WeightLow
10/23/2020HC WainwrightLower Price TargetNeutral$272.00 ➝ $265.00Medium
10/13/2020BarclaysReiterated RatingEqual WeightMedium
10/6/2020Bank of AmericaBoost Price TargetBuy$265.00 ➝ $298.00Low
10/6/2020Robert W. BairdBoost Price TargetPositive ➝ Outperform$265.00 ➝ $275.00Low
10/5/2020JMP SecuritiesBoost Price TargetOutperform$245.00 ➝ $271.00High
9/30/2020Piper SandlerBoost Price TargetPositive ➝ Overweight$258.00 ➝ $300.00Low
8/24/2020Raymond JamesInitiated CoverageOutperform$257.00Medium
8/10/2020Morgan StanleyBoost Price TargetOverweight$258.00 ➝ $281.00Medium
7/31/2020Kepler Capital MarketsDowngradeBuy ➝ HoldLow
7/30/2020Stifel NicolausReiterated RatingBuy$253.00Medium
7/29/2020HC WainwrightInitiated CoverageNeutral$272.00High
6/17/2020CowenReiterated RatingBuyLow
5/29/2020JPMorgan Chase & Co.Boost Price TargetOverweight$179.00 ➝ $246.00Medium
5/27/2020Morgan StanleyBoost Price TargetOverweight$180.00 ➝ $258.00Low
5/27/2020GuggenheimReiterated RatingBuy$201.00 ➝ $225.00Medium
5/27/2020Robert W. BairdBoost Price TargetPositive ➝ Outperform$170.00 ➝ $235.00Medium
5/27/2020SunTrust BanksBoost Price TargetBuy$192.00 ➝ $240.00Medium
5/26/2020JMP SecuritiesBoost Price TargetOutperform$170.00 ➝ $237.00High
5/26/2020Piper SandlerBoost Price Target$198.00 ➝ $258.00High
5/26/2020Stifel NicolausBoost Price TargetPositive ➝ Buy$163.00 ➝ $253.00High
5/21/2020Credit Suisse GroupBoost Price TargetNeutral$150.00 ➝ $160.00Medium
5/17/2020NomuraReiterated RatingBuy$255.00High
5/14/2020Stifel NicolausReiterated RatingBuy$163.00High
3/4/2020Nomura SecuritiesReiterated RatingBuy$255.00High
2/24/2020GuggenheimBoost Price TargetBuy$164.00 ➝ $201.00Low
2/10/2020Bank of AmericaInitiated CoverageBuy$181.00Low
1/17/2020WedbushReiterated RatingOutperform$184.00 ➝ $184.00Low
1/17/2020Morgan StanleyBoost Price TargetOverweight$170.00 ➝ $180.00Medium
1/9/2020WedbushBoost Price TargetPositive ➝ Outperform$179.00 ➝ $184.00Medium
1/9/2020JMP SecuritiesReiterated RatingOutperform$164.00 ➝ $170.00Medium
1/9/2020Stifel NicolausReiterated RatingBuy ➝ AverageHigh
1/6/2020Piper Jaffray CompaniesBoost Price TargetOverweight$177.00 ➝ $194.00N/A
12/16/2019SunTrust BanksBoost Price TargetBuy$160.00 ➝ $192.00Medium
12/8/2019Stifel NicolausBoost Price TargetBuy$154.00 ➝ $170.00High
11/18/2019SunTrust BanksBoost Price TargetBuy$150.00 ➝ $160.00Low
11/8/2019Piper Jaffray CompaniesReiterated RatingOverweightLow
11/5/2019Credit Suisse GroupInitiated CoverageNeutral$137.00 ➝ $137.00Low
10/31/2019William BlairUpgradeMarket Perform ➝ OutperformLow
10/22/2019JPMorgan Chase & Co.Initiated CoverageOverweight$167.00Low
9/27/2019Wells Fargo & CompanyInitiated CoverageMarket Perform$125.00Medium
9/13/2019CowenInitiated CoverageBuyMedium
8/6/2019Morgan StanleyBoost Price TargetOverweight$143.00 ➝ $173.00Medium
8/2/2019WedbushBoost Price TargetOutperform$144.00 ➝ $170.00Low
8/1/2019Stifel NicolausReiterated RatingBuy$154.00Low
6/27/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$170.00High
5/23/2019Piper Jaffray CompaniesBoost Price TargetOverweight$161.00 ➝ $182.00High
5/22/2019Stifel NicolausSet Price TargetBuy$154.00High
3/1/2019WedbushBoost Price TargetOutperform ➝ Outperform$131.00 ➝ $144.00Medium
2/22/2019GuggenheimInitiated CoverageBuy$157.00High
2/4/2019Stifel NicolausReiterated RatingBuyLow
1/18/2019SunTrust BanksReiterated RatingBuy ➝ BuyLow
1/4/2019Morgan StanleyInitiated CoverageOverweight ➝ Overweight$140.00Low
12/17/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$154.00Low
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformLow
12/9/2018CowenReiterated RatingBuyLow
12/4/2018Piper Jaffray CompaniesBoost Price TargetOverweight$154.00 ➝ $161.00Low
12/4/2018WedbushBoost Price TargetOutperform ➝ Outperform$130.00 ➝ $131.00Medium
11/5/2018WedbushReiterated RatingOutperform ➝ Outperform$130.00 ➝ $125.00Medium
11/1/2018Stifel NicolausReiterated RatingBuyHigh
10/25/2018Stifel NicolausSet Price TargetBuy$139.00Low
10/16/2018Stifel NicolausSet Price TargetBuy$139.00High
10/15/2018Evercore ISIInitiated CoverageOutperform$110.00Medium
10/10/2018Stifel NicolausReiterated RatingBuy$139.00High
9/18/2018SunTrust BanksBoost Price TargetBuy ➝ In-Line$132.00High
9/18/2018WedbushBoost Price TargetOutperform ➝ Positive$114.00 ➝ $121.00High
9/17/2018JMP SecuritiesBoost Price TargetOutperform$150.00High
9/17/2018Piper Jaffray CompaniesReiterated RatingPositive ➝ Overweight$154.00High
9/13/2018Stifel NicolausInitiated CoverageBuy$139.00High
6/29/2018Nomura SecuritiesInitiated CoverageBuy$161.00High
6/25/2018WedbushBoost Price TargetOutperform ➝ Outperform$93.00 ➝ $114.00High
6/18/2018JMP SecuritiesBoost Price TargetPositive$93.00 ➝ $130.00Low
6/14/2018CowenReiterated RatingBuyLow
6/7/2018Piper Jaffray CompaniesReiterated RatingOverweight$130.00Medium
6/6/2018CowenReiterated RatingBuyHigh
5/10/2018WedbushReiterated RatingOutperform$93.00 ➝ $92.00Low
4/26/2018WedbushBoost Price TargetOutperform ➝ Outperform$88.00 ➝ $92.00Low
4/8/2018SunTrust BanksInitiated CoverageBuy ➝ Buy$125.00High
1/29/2018JMP SecuritiesBoost Price TargetMkt Outperform ➝ Outperform$74.00 ➝ $87.00High
12/19/2017Piper Jaffray CompaniesBoost Price TargetOverweight$100.00Low
11/16/2017WedbushReiterated RatingOutperform$26.00 ➝ $41.00N/A
8/24/2017CowenReiterated RatingBuyLow
6/12/2017WedbushReiterated RatingOutperformHigh
6/12/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$33.00High
6/12/2017CowenInitiated CoverageOutperformHigh
(Data available from 6/23/2016 forward)
argenx logo
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Read More

Today's Range

Now: $312.15
Low: $310.66
High: $316.59

50 Day Range

MA: $282.92
Low: $257.11
High: $319.92

52 Week Range

Now: $312.15
Low: $212.66
High: $382.15


87,258 shs

Average Volume

194,288 shs

Market Capitalization

$16.02 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of argenx?

The following equities research analysts have issued stock ratings on argenx in the last twelve months: Bank of America Co., Barclays PLC, Cowen Inc, Guggenheim, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Kepler Capital Markets, Morgan Stanley, Piper Sandler, Raymond James, Redburn Partners, Robert W. Baird, Stifel Nicolaus, Truist Financial Co., UBS Group AG, Wedbush, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for ARGX.

What is the current price target for argenx?

13 Wall Street analysts have set twelve-month price targets for argenx in the last year. Their average twelve-month price target is $332.15, suggesting a possible upside of 5.2%. Cowen Inc has the highest price target set, predicting ARGX will reach $430.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $250.00 for argenx in the next year.
View the latest price targets for ARGX.

What is the current consensus analyst rating for argenx?

argenx currently has 6 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARGX will outperform the market and that investors should add to their positions of argenx.
View the latest ratings for ARGX.

What other companies compete with argenx?

How do I contact argenx's investor relations team?

argenx's physical mailing address is Willemstraat 5, Breda P7, 4811 AH. The company's listed phone number is 329-310-3400 and its investor relations email address is [email protected] The official website for argenx is